Abstract

BackgroundColorectal cancer (CRC) is the third most prevalent cancer type and the third leading cause of cancer-related deaths worldwide, it is urgently needed to discover a new marker for the progress of CRC. Many long noncoding RNAs (lncRNAs) have been reported to be abnormally expressed in CRC, and may be feasible as effective biomarkers and prognostic factors. The aim of this study was to identify the prognostic value of various lncRNAs in CRC.MethodsPubmed, Web of Science, Embase and Cochrane Library were searched for potentially related studies. A total of 34 eligible studies including 30 on overall survival (OS), 7 on disease-free survival (DFS), 1 on relapse-free survival (RFS), 2 on disease-specific survival (DSS) and 29 on clinicopathological features were qualified from the databases.ResultsThe results showed that the expression levels of lncRNAs were significantly associated with poor OS (hazard ratio (HR) = 2.08, 95% confidence interval (CI) = 1.68–2.57, P<0.001, I2 = 70%), DFS (HR = 1.79, 95% CI = 1.54–2.08, P<0.001, I2 = 6%) and DSS (HR = 0.11, 95% CI = 0.02–0.54, P = 0.007, I2 = 14%). Subgroup analysis further showed that lncRNA transcription level was significantly associated with tumor differentiation (odds ratio (OR) = 0.51, 95% CI = 0.34–0.77, P = 0.001), lymph node metastasis (OR = 1.63, 95% CI = 1.23–2.17, P = 0.0007), distant metastasis (OR = 2.06, 95% CI = 1.29–3.30, P = 0.002), TNM stage (OR = 0.44, 95% CI = 0.32–0.62, P<0.001), tumor invasion depth (OR = 0.48, 95% CI = 0.39–0.60, P<0.001).ConclusionsThe meta-analysis demonstrated that abnormal lncRNA transcription level may serve as a promising indicator for prognostic of patients with CRC.

Highlights

  • Colorectal cancer (CRC) is one of the most common malignancies, which ranks the third in the cancer morbidity and the second in the cancer mortality worldwide, with an annual 1.3 million new CRC cancer cases and 694,000 deaths according to the GLOBOCAN estimations [1, 2]

  • The results showed that the expression levels of long noncoding RNAs (lncRNAs) were significantly associated with poor overall survival (OS) (hazard ratio (HR) = 2.08, 95% confidence interval (CI) = 1.68–2.57, P

  • Subgroup analysis further showed that lncRNA transcription level was significantly associated with tumor differentiation (odds ratio (OR) = 0.51, 95% CI = 0.34–0.77, P = 0.001), lymph node metastasis (OR = 1.63, 95% CI = 1.23–2.17, P = 0.0007), distant metastasis (OR = 2.06, 95% CI = 1.29–3.30, P = 0.002), Tumor node metastasis (TNM) stage (OR = 0.44, 95% CI = 0.32–0.62, P

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most common malignancies, which ranks the third in the cancer morbidity and the second in the cancer mortality worldwide, with an annual 1.3 million new CRC cancer cases and 694,000 deaths according to the GLOBOCAN estimations [1, 2]. Relapse and metastasis are major factors for the poor outcome of CRC patients[5]. Accumulating evidences showed that lncRNAs played pivotal roles in various cancers and were associated with tumor cell proliferation, apoptosis, invasion and metastasis[10, 11]. LncRNA H19 was significantly up-regulated in the plasma of Gastric Cancer (GC) patients, and could be a potential non-invasive diagnostic biomarker in GC[13]. In non-small cell lung cancer, upregulation of long non-coding RNA ATB, a TGF-β-activated lncRNA, indicated a poor prognosis by regulating cell proliferation and metastasis[15]. Recent mounting studies have shown that lncRNAs are potential diagnostic and prognostic biomarkers of CRC. Many long noncoding RNAs (lncRNAs) have been reported to be abnormally expressed in CRC, and may be feasible as effective biomarkers and prognostic factors. The aim of this study was to identify the prognostic value of various lncRNAs in CRC

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.